echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Prevention of COVID-19 Lilly in the elderly and antibody effectiveness of up to 80%

    Prevention of COVID-19 Lilly in the elderly and antibody effectiveness of up to 80%

    • Last Update: 2021-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Bamlanivimab, a medium-to-moderate COVID-19 targeted at the new coronavirus prickly protein, has been granted emergency use authorization (EUA) by the FDA to treat high-risk patients.
    that although several new crown vaccines have been approved for EUA, it will still take weeks for the new crown vaccine to be effective.
    and for some older people or patients with suppressed immune systems, their immune systems may not respond adequately to vaccines.
    antibodies as a preventive therapy is effective immediately after the drug is given, and is equally effective in the elderly and patients with suppressed immune systems.
    In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, 965 subjects (299 nursing home residents and 666 staff) who tested negative for the new coronavirus at baseline were included in the evaluation and analysis of antibody prevention effectiveness.
    subjects were randomly treated with 4200 mg bamlanivimab or a placebo.
    after 8 weeks of follow-up in all subjects, the frequency of symptomatic COVID-19 in the bamlanivimab treatment group was significantly lower than in the placebo group (odd ratio=0.43, p=0.00021).
    in the pre-defined subgroup of nursing home residents, the frequency of symptomatic COVID-19 patients in patients treated with bamlanivimab was also significantly reduced compared to placebo (odd ratio 0.20; p=0.00026).
    results showed that residents who received bamlanivimab randomly had an 80 percent lower risk of contracting COVID-19 than those who received a placebo and lived in the same facility.
    four of the 299 residents in the prevention group were caused by COVID-19, all of which occurred in the placebo group and none in the bamlanivimab group.
    Dr Daniel Skovronsky, Chief Scientific Officer and President of Lilly Research Laboratories, said: "We are very pleased with these positive results, which demonstrate that bamlanivimab can help prevent COVID-19 and significantly reduce the risk of illness among nursing home residents, who are among the most vulnerable members of society.
    we look forward to working with regulators to extend the scope of emergency use authorizations (EUA) to prevent the spread of COVID-19 in these facilities.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    : s neutralizing antibody bamlanivimab (LY-CoV555) prevention COVID-19 at nursing homes in the BLAZE-2 trial, reducing risking by up to 80 percent for residents. Retrieved January 21, 2021, from
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.